Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04594798
Recruitment Status : Recruiting
First Posted : October 20, 2020
Last Update Posted : January 11, 2022
Genentech, Inc.
Information provided by (Responsible Party):
Patrick Reagan, University of Rochester

Brief Summary:
The purpose of this study is to test the effectiveness and safety of polatuzumab vedotin in combination with R-miniCHP in patients 75 years and older with DLBCL.

Condition or disease Intervention/treatment Phase
DLBCL Lymphoma, B-Cell Drug: Polatuzumab vedotin Drug: Rituximab Drug: Cyclophosphamide Drug: Doxorubicin Drug: Prednisone Phase 2

Detailed Description:
In this study, the investigator would like to better understand the efficacy and safety of the addition of polatuzumab vedotin to therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) and dose attenuated R-CHOP in patients who are aged 75 years and older.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 39 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 2 Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL
Actual Study Start Date : September 20, 2021
Estimated Primary Completion Date : July 31, 2024
Estimated Study Completion Date : July 31, 2024

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Experimental: Polatuzumab Vedotin and R-CHOP
The dose of polatuzumab vedotin for each patient will be 1.8 mg/kg (IV for 21 days)
Drug: Polatuzumab vedotin
IV 1.8 mg/kg per cycle

Drug: Rituximab
IV 375 mg/m2 per cycle

Drug: Cyclophosphamide
IV 400 mg/m2 per cycle

Drug: Doxorubicin
IV 25 mg/m2 per cycle

Drug: Prednisone
PO 40 mg/m2 per cycle

Primary Outcome Measures :
  1. Progression Free Survival [ Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months ]
    Measure of time from study enrollment until progression.

Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: From date of enrollment until date of death from any cause up to 24 months ]
    Measure of time from study enrollment until death from any cause.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   75 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Voluntary written informed consent before performance of any study-specific procedure not part of routine medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care. Subjects must be able to understand and be willing to sign the written informed consent form.
  • Men and women aged greater than or equal to 75 years of age
  • ECOG performance status of 0-3
  • Histologically-confirmed DLBCL, NOS, NOS, high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements, high grade B-cell lymphoma, NOS, and grade 3b follicular lymphoma by 2016 WHO classification by site hematopathologist

    • Histologic transformation (HT) will be included on the study. This must be confirmed with a biopsy. Patients with HT may have received prior treatment for indolent lymphoma including chemoimmunotherapy, but must not have received an anthracycline-containing regimen in the past. Patients with Richter's transformation will be eligible.
    • Composite and discordant lymphomas containing both indolent and large cell features will be included
  • Has received no prior therapy for aggressive B-cell lymphoma or HT with the following exceptions:

    • A course of corticosteroids given for lymphoma related symptoms.
    • A course of cyclophosphamide or vincristine with or without steroids given for lymphoma related symptoms.
    • One cycle of anthracycline containing chemotherapy such as R-CHOP or R-miniCHOP given urgently for aggressive disease.

Patient is not felt to be a candidate for standard dose R-CHOP due to age or comorbidities, per the site investigator.

  • Ejection fraction of ≥ 45% on echocardiogram or MUGA
  • Patient has a platelet count of ≥75,000/μL within 14 days before enrollment unless inadequate function is due to bone marrow infiltration with aggressive B-cell lymphoma
  • Patient has an absolute neutrophil count of ≥1,500/ μL within 14 days before enrollment unless inadequate function is due to bone marrow infiltration with aggressive B-cell lymphoma
  • Patient has a calculated or measured creatinine clearance of >30 mL/minute within 14 days before enrollment.
  • Total bilirubin must be less than 1.5 times the upper limit of normal (ULN) unless the elevation is known to be due to Gilbert syndrome or hepatic involvement with aggressive B-cell lymphoma in which case it can be ≤ 3.0 times the ULN.
  • ALT or AST must be ≤ 2.5 times the ULN.
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined below:

    • With female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 5 months after the last dose of polatuzumab vedotin to avoid exposing the embryo or fetus for the duration of the pregnancy. Men must refrain from donating sperm during this same period.
    • The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of preventing drug exposure. Male patients considering preservation of fertility should bank sperm before study treatment.

Exclusion Criteria:

  • History of, or clinically apparent central nervous system (CNS) lymphoma
  • Primary mediastinal B-cell lymphoma or EBV positive DLBCL
  • Patient is receiving peritoneal dialysis or hemodialysis
  • Patient has > Grade 1 peripheral neuropathy.
  • New York Heart Association class III heart failure or EF <45%
  • Patient has received other investigational drugs with 14 days before enrollment
  • Prior exposure to anthracycline except for one cycle of therapy given urgently for lymphoma.
  • Patient has concomitant active malignancy that the treating physician or PI feels may interfere with the ability to measure the primary or secondary outcomes

    • Patients with stage 1 cancers are eligible after definitive treatment.
    • Patients with low grade prostate cancer who are managed with observation are eligible.
    • Patients with other malignancies that have been treated with curative intent will be included if they are in documented remission without treatment for ≥ 3 years prior to enrollment.
  • Patient is known to be HIV positive (test result not required for enrollment).
  • Patient has active hepatitis B with a positive surface antigen or viral load. Carriers of hepatitis B virus should be closely monitored for clinical and laboratory signs of active HBV infection and for signs of hepatitis throughout study participation according to national and local guidelines. Those at high risk of reactivation should be placed on appropriate antiviral therapy as per national guidelines.
  • History of solid organ transplantation, or post-transplant lymphoproliferative disorder
  • Patient has history of allogeneic stem cell transplantation.
  • Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
  • Any clinically significant abnormality in screening blood chemistry, hematology, or urinalysis results that, in the judgment of the investigator, would impede adequate evaluation of adverse

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04594798

Layout table for location contacts
Contact: Krista French (585) 276-5812

Layout table for location information
United States, New York
University of Rochester Recruiting
Rochester, New York, United States, 14642
Sponsors and Collaborators
University of Rochester
Genentech, Inc.
Layout table for investigator information
Principal Investigator: Patrick Reagan University of Rochester
Layout table for additonal information
Responsible Party: Patrick Reagan, Assistant Professor - Department of Medicine , Hematology/Oncology (SMD), University of Rochester Identifier: NCT04594798    
Other Study ID Numbers: ULYM20030
First Posted: October 20, 2020    Key Record Dates
Last Update Posted: January 11, 2022
Last Verified: January 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Patrick Reagan, University of Rochester:
polatuzumab vedotin
Lymphoma, B-Cell
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antineoplastic Agents, Immunological
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Anti-Inflammatory Agents